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Omega-3 fatty acids (n-3 FA) supplementation has been widely
used regardless the initial FA composition of the studied popula-
tion. In this work we compared the red blood cell FA (RBC-FA)
composition in healthy and different diseased populations at
baseline and show how this affects the incorporation of n-3 FA
supplementation in ICU-trauma patients. Blood was drawn from
Healthy (H, n ¼ 22), Psoriasis (P, n ¼ 13), Cancer(C, n ¼ 81),
Geriatric (G, n ¼ 49), Social-phobia (SP, n ¼ 27) and ICU-trauma (T,
n ¼ 40) patients before n-3 FA supplementation. For the T group
blood was also drawn 8 days after receiving a formula with 4.1 g/L
EPA and 5.5 g/L GLA (Oxepa, Abbott). RBC-FA was assessed by gas
chromatography and the percentage of each FA was calculated in
relation to the total identiﬁed FAs. Baseline RBC-FA proﬁle was
signiﬁcantly different between groups (p < 0.0001) with subjects
in the healthy group having higher n-3 FA status. H and SP showed
the highest content in total n-3 FA (11.89 ± 0.22% H vs 7.45 ± 0.26%
T) and EPA (1.61 ± 0.03% H vs 0.41 ± 0.13% P). DHA was higher in C
and H than in the other groups (6.15 ± 0.15% C vs 4.32 ± 0.11% T).
ARA was highest in C (16.04 ± 0.20% C vs 14.85 ± 0.22% H) and
comparable in the rest of the groups. The n-6/n-3 ratio was lowest
for H and highest for T (2.75 ± 0.07 vs 4.96 ± 0.13). Moreover, we
showed that for the T group, the treatment-associated changes in
the n-3 content are dependent on the initial n-3 FA status, since a
negative correlation between the baseline omega 3 index
(EPA þ DHA) and its change after supplementation was foundResearch, Felsenstein Medical Research Center, Room 106, Beilinson Hos-
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evaluated and considered individually for each patient or groups
before generalized supplementation schemes, strengthening the
concept of personalized medicine.
© 2015 The Authors. Published by Elsevier Ltd on behalf of
European Society for Clinical Nutrition and Metabolism. This is an
open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Omega-3 fatty acids (n-3 FAs) are considered essential dietary components with proven beneﬁcial
effects on several pathologies [1,2]. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are
precursors of numerous bioactive mediators important in anti-inﬂammatory processes [3], signal
transduction [4] and gene expression [5]. These bioactive molecules are consumed in the human diet
mainly through fatty ﬁsh, but their popularity rose mainly due to their use as a supplement in both
health and pathology. The WHO recommends an intake of 0.2e0.5 g/d of EPA and DHA for the
prevention of some chronic diseases, however natural intake of this compounds vary among pop-
ulations and cultures. Research on the effects of n-3 FAs consumption has increased signiﬁcantly in
the past years where the dietary or supplementary intake of n-3 FAs is assessed by following their
content in a variety of biological compartments directly reﬂecting n-3 FA intake [6]. The most
common cell population used for this purpose is red blood cells (RBC), which can be easily accessed
and respond directly to the dose of n-3 intake [2]. RBC also allow the calculation of the omega 3 index
(O3I, %EPAþ %DHA of total identiﬁed FA), which has been used as a biomarker of n-3 intake [7] and as
a risk marker for several diseases, mainly cardiovascular [8]. Moreover, it constitutes a useful tool as a
ﬁrst approach when comparing results among publications. It was shown that O3I response to n-3
FAs was inﬂuenced by initial values and dose of supplementation, and appears to be an important
predictor of therapeutic efﬁcacy of n-3 supplementation [9,10]. The basal level, rate and extent of
incorporation of n-3 FAs can be inﬂuenced by factors such as, concurrent intake of vitamin/minerals
and gender [11], age and smoking [12], physical activity and body weight [13], genetics [14] and even
the existence of a certain pathology [15e18]. All of which can have an effect on either the normal
metabolic functioning or dietary habits, directly inﬂuencing the availability of n-3 FAs. The initial
status of the membrane's FA composition is not usually taken into consideration when planning
supplementation doses and duration, nor is the nature of the target population. Furthermore, it was
shown that high doses of dietary n-3 FAs, as well as long-time treatments could be detrimental [1,19].
In this sense it is important to characterize the basal FA composition of a certain population before
any supplementation plan is applied, in order to understand better the possible outcomes of the
study. In this work we compared the RBC-FA composition in healthy and different diseased pop-
ulations at baseline and show how this affects the incorporation of n-3 FA into RBC after supple-
mentation in ICVU-trauma patients.
2. Materials and methods
2.1. Patient groups and blood samples
Blood was drawn from Healthy (group H, n ¼ 22), Psoriasis (group P, n ¼ 13), Cancer (group C,
n ¼ 81), Geriatric (group G, n ¼ 49), Social-phobia (group SP, n ¼ 27) and ICU-trauma (group T, n ¼ 40)
patients before any n-3 FA supplementation. Group G consisted of patients admitted electively from
home to the hospital for hip or knee replacement surgery as part of a different study. Group T further
received a formula supplemented with 4.1 g/L EPA and 5.5 g/L GLA (Oxepa, Abbott) upon admission in
the ICU as part of a different study [20]. An extra sample of blood was drawn 8 days after supple-
mentation started, that was used to study the rate of FA incorporation into RBC membranes. Study
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for each participant prior to intervention.
2.2. Fatty acid analysis
Whole blood was drawn into EDTA-containing vacutainer tubes. After centrifugation, the plasma
and buffy coat were removed. RBC were washed 3 times with 0.9% NaCl and kept under N2 at 70 C
until analysis. Lipid extraction was performed by homogenization of the cells in hexane/isopropanol
(3:2 vol/vol) containing 5mg/dl butylated hydroxytoluene (BHT) as an antioxidant. FAs were converted
to methyl esters (FAMEs) by heating with BF3 in methanol, and FAMEs were separated on a HP 5890
Series II Gas Chromatograph containing a ﬂame ionization detector. Heliumwas used as the carrier gas
at 1mL/min, and nitrogen as themake-up gas at 30mL/min. A split of 1:30 was usedwith the following
running conditions: initial temperature: 150 C for 2 min, increasing at a rate of 3 C/min to 240 C and
kept for 10min until the end of the run (40min). Peak areas were integrated and plottedwith the aid of
the Varian Star Integrator computer package (Varian Star Workstation, 1990, Varian Associates, Inc.).
Individual FAMEs were identiﬁed by comparing retention times with authentic standards. Values were
expressed as percentage of a given FA in respect to total identiﬁed fatty acids. The omega 3 index (O3I)
was calculated by adding together the EPA and DHA percentages for each sample.
The data regarding the RBC-FA composition of groups H, P, C and SP were obtained in previous
studies involving these populations and were kindly provided by Dr. Pnina Green for comparison with
the other populations studied here. The SP study has been previously published [21].
Statistical analysis was performed by either One Way-ANOVA (OW-ANOVA) þ Post-Hoc Tukey's
Multiple Comparison Test (MCT) or Pearson's test with the assistance of GraphPad Prism 5.00 software.
Results are expressed as Mean ± SEM and signiﬁcance level was set to p < 0.05.
3. Results
3.1. The RBC-FA composition depends on the nature of the population
The characteristics of the different populations studied regarding sex, age and body mass index
(BMI) are presented in Table 1.
Signiﬁcant differences (p< 0.0001) in the RBC-FA proﬁle between populations were found, the
amount of the main n-3 and n-6 FAs and related parameters are summarized in Table 2. Groups H and
SP showed the highest content in both EPA alone (Fig. 1; 1.61± 0.03% H vs 0.41± 0.13% P) and total n-3
FAs (Fig. 2; 11.89± 0.23% H vs 7.45± 0.16% T). DHAwas higher in groups C and H than in the rest of the
groups (Fig. 1; 6.15± 0.15% C vs 4.32± 0.11% T). n-6 arachidonic acid (ARA) was highest in group C
(Fig. 1; 16.04± 0.20% C vs 14.85± 0.22% H) and comparable in the rest of the groups. The n-6/n-3 ratio
was lowest for group H and highest for group T (Fig. 2; 2.75± 0.07 vs 4.96± 0.13).Table 1
Population characteristics.
Group n Age (years) Sex BMI
Psoriasis 13 NA NA NA
Cancer 81 62.4 ± 1.3 36 (F) NA
44 (M)
Trauma 40 46.3 ± 2.8 9 (F) 25.9 ± 0.6
31 (M)
Geriatric 49 68.9 ± 1.3 37 (F) 30.5 ± 0.8
12 (M)
Social phobia 27 31.7 ± 1.5 14 (F) 22.9 ± 0.6
13 (M)
Healthy 22 35.2 ± 2.0 14 (F) 23.3 ± 0.8
13 (M)
Results are shown as mean ± SEM.
NA: information not available; (F): Females; (M): Males.
Table 2
RBC-FA composition of the different studied populations. Only main FAs and total parameters are presented. Signiﬁcant differences between groups are identiﬁed by superscripts. Per-
centage (%) of each FA in relation to the total FAs identiﬁed is expressed as mean ± SEM.
Parameter Psoriasis (P) Cancer (C) Trauma (T) Geriatric (G) Social phobia (SP) Healthy (H)
16:0 20.86 ± 0.48a,h,I,z 18.87 ± 0.11b,g,h,z 22.33 ± 0.19a,b,c,d 22.18 ± 0.17,e,f,g,1 19.67 ± 0.09c,e,j 19.51 ± 0.16d,f,1
18:0 18.04 ± 0.40a,d,g 16.22 ± 0.12g,h,i 17.40 ± 0.11b,e,h 17.78 ± 0.20c,f,i 15.93 ± 0.10a,b,c 15.79 ± 0.13d,e,f
LA 18:2 n-6 10.07 ± 0.25z 9.57 ± 0.17a,d 10.02 ± 0.20b,1,2 9.07 ± 0.16c,e,1 11.43 ± 0.23a,b,c,z 11.25 ± 0.18d,e,2
ALA 18:3 n-3 0.11 ± 0.01¶ 0.05 ± 0.01a,b,c,# 0.21 ± 0.04a,z,¶ 0.16 ± 0.01b 0.13 ± 0.01z,# 0.19 ± 0.01c
ARA 20:4 n-6 13.57 ± 0.65a,1,z 16.04 ± 0.20a,# 14.94 ± 0.22 15.43 ± 0.201 15.41 ± 0.18z 14.85 ± 0.25#
EPA 20:5 n-3 0.38 ± 0.13a,e 0.62 ± 0.08b,f 0.81 ± 0.13c,g 0.61 ± 0.04d,h 1.62 ± 0.06a,b,c.d 1.61 ± 0.04e,f,g,h
DPA 22:5 n-3 2.29 ± 0.10a,e,i 3.02 ± 0.07b,f,I,j,k 2.42 ± 0.09c,g,j 2.48 ± 0.04d,h,k 4.59 ± 0.14a,b,c,d 4.29 ± 0.07e,f,g,h
DPA n-6 22:5 n-6 1.17 ± 0.471,2,z,# 0.65 ± 0.021 0.78 ± 0.10 0.60 ± 0.022 0.67 ± 0.03z 0.58 ± 0.03#
DHA 22:6 n-3 4.66 ± 0.41a,# 6.15 ± 0.15a,b,c,d 4.67 ± 0.18b,z 4.86 ± 0.15c 4.60 ± 0.19d 5.62 ± 0.24z,#
Total n-3 7.56 ± 0.54d,e 9.91 ± 0.22a,b,c,d,z 8.14 ± 0.27a,g 8.19 ± 0.20b,f 11.06 ± 0.22e,f,g,z 11.89 ± 0.25c
Total n-6 29.42 ± 1.08a,b,c,1,z 32.18 ± 0.33,1,2,# 34.02 ± 0.38a,2 33.52 ± 0.26b 33.40 ± 0.32c 32.34 ± 0.35z,#
Total SFA 45.72 ± 1.10a,d,g 40.92 ± 0.22a,b,c 44.31 ± 0.30b,e,h 44.83 ± 0.30c,f,i 39.92 ± 0.14d,e,f 39.85 ± 0.11g,h,i
Total MUFA 17.24 ± 0.32a,1 13.52 ± 0.20a,b,c,d,e 16.30 ± 0.17b 16.67 ± 0.18c,2 15.62 ± 0.21d,1,2 15.93 ± 0.20e
n-6/n-3 4.14 ± 0.33g,1 3.40 ± 0.10a,d,z 4.41 ± 0.19a,b,c 4.23 ± 0.12d,e,f 3.06 ± 0.09b,e 2.75 ± 0.08c,f,g,1,z
O3I (EPA þ DHA) 5.04 ± 0.52a,1 6.77 ± 0.18d,e,1 5.09 ± 0.25b,d,z 5.48 ± 0.18c,e 6.22 ± 0.18z 7.23 ± 0.24a,b,c
LA, linoleic acid; ALA, a-linolenic acid; DPA, docosahexaenoic acid; DPA n-6, docosapentaenoic acid; SFA, saturated FAs; MUFA, medium chain unsaturated FAs. Results are shown as
mean ± SEM.
OW-ANOVA þ Tukey's MCT, aek: signiﬁcance level p < 0.001 (***); 12: signiﬁcance level p < 0.01 (**); z, #, ¶: signiﬁcance level p < 0.05 (*).
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Fig. 1. Main n-6 and n-3 FAs content in the different populations. The amount (%) of ARA, EPA and DHAwas calculated for each population in respect to the total amount of FAs identiﬁed. OW-
ANOVA þ Tukey's MCT. Signiﬁcant differences among groups were found and are represented in the ﬁgures according to signiﬁcance level: aeh; p < 0.001 (***); 1; p < 0.01 (**); ‡, #; p < 0.05 (*).
The average and SEM for each population are shown in grey lines.
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identiﬁed FAs was calculated and used to determine the n-6/n-3 ratio. O3I was calculated as %EPAþ %DHA for each group. OW-
ANOVA þ Tukey's MCT. Signiﬁcant differences among groups were found and are represented in the ﬁgures according to signiﬁcance
level: aeg; p < 0.001 (***); 1e2; p < 0.01 (**); ‡, #; p < 0.05 (*). The average and SEM for each population are shown in grey lines.
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We showed that after group T received a formula supplemented with n-3 FAs for a period of 8 days,
the content of EPA increased signiﬁcantly but no change was observed in DHA levels (Table 3).
The calculated O3I signiﬁcantly increased from 5.09± 0.26% to 6.56± 0.24% (p< 0.0001) after 8 days
of supplementation (Fig. 3A). Furthermore, a signiﬁcant negative correlation (p¼ 0.002) between the
baseline O3I and its change after supplementation was found (Fig. 3B).
4. Discussion
In this comparative study we evaluated the RBC-FA composition of six populations that differed in
their nature. Populations analysed included groups of patients with various pathological conditions
such as cancer, psoriasis, social phobia, ICU-trauma as well as a group of geriatric patients and healthy
volunteers. Omega 3 supplementation has been used in this type of populations for the prevention
and/or treatment of their diseases [1,2] with contradictory results for some of them [22]. The source of
such contradictions in the literature may be due to the lack of standardized supplementation plans,
mainly in terms of dose and duration, but also because of the disregard of the pre-existing amount of n-
3 FAs in their cell membranes. Here we showed that the baseline FA composition of RBC varies ac-
cording to the nature of the population under study. It was already shownhowdifferent factors, such as
gender, age or lifestyle affect the rate of incorporation of FAs but comparisons between different
diseased populations that comprise a valid and already studied target of n-3 supplementation was
never performed. In our study the healthy subjects group had the highest omega 3 status, with a total
Table 3
Effect of n-3 supplementation on EPA and DHA levels (% total FAs) in group T.
Fatty acid Baseline Day 8 p value
EPA 0.81 ± 0.13% 2.23 ± 0.16% <0.0001
DHA 4.67 ± 0.18% 4.58 ± 0.12% 0.5483
Results are shown as mean ± SEM.
Paired t test.
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Fig. 3. O3I response to supplementation. A. Calculated O3I for group T before (baseline) and after an 8-days n-3 supplementation
plan. Paired t test, p < 0.0001. The average and SEM are shown in grey lines. Dotted line represents an O3I equivalent to 8%. B.
Correlation between baseline and change of O3I (O3IDay8 e O3Ibaseline) after supplementation. Pearson's test, p ¼ 0.002, r ¼ 0.4677,
r2 ¼ 0.2187.
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patients, but comparable to that found in social phobia patients. The amount of the main n-3 FAs, EPA
and DHA was also variable among the populations. EPA is more than double in the healthy and social
phobia groups in comparison to the rest of the groups. In contrast, DHA is highest in the cancer group,
followed by the healthy and geriatric groups, all the rest have comparable values. Regarding the n-6
status of the different populations, the psoriasis group is the one with the lowest amount of total n-6
FAs and speciﬁcally ARA, all the rest of the groups had comparable amounts. We can infer that the
source of such variations among our populations is due to the presence/absence of their speciﬁc dis-
eases, more likely than any other factor, but other modiﬁers weren't evaluated and are not in the scope
of this work. It is already known that the dysregulation of FA metabolism is connected to the devel-
opment and maintenance not only of diseases such as cardiovascular diseases, metabolic and nutri-
tional disease, but also to cancer [23,24] and psoriasis [25] for example. The change in lifestyle and
dietary habits associated to age, disease, hospitalization, etc., might also alter the lipid metabolism of a
given individual and therefore alter the availability of the different FA in their cell membranes.
In this study we also showed that when one of the populations was supplemented with n-3 FA, the
extent of incorporation of the FAs was dependent on the baseline status of each individual. Those with
lower baseline O3I values incorporated the n-3 FAs more efﬁciently than those with higher O3I, sug-
gesting that those patients with a worst n-3 status may beneﬁt the most from the supplementation
plan. Similar results were obtained by Keenan et al. where they implied the existence of response
thresholds in an n-3 supplemented healthy population. They found that the O3I response to n-3 FAs
was inﬂuenced by initial values and dose, and appears to be an important predictor of therapeutic
efﬁcacy of n-3 supplementation. They also found that to maintain levels of O3I in the range for car-
dioprotective effects (>8%) a dose of 7 mg/kg/day of n-3 FAs is needed, which is double the amount
suggested by different health institutions [9]. If we consider the 8% O3I as a relative threshold in our
supplemented population, we can see that only 15% (6/40) of the patients reached such O3I level after
supplementation, suggesting that probably our dose or time of supplementation wasn't enough to
accomplish such beneﬁcial effects. This was discussed in a recent article describing the clinical results
of preemptive administration of EPA and GLA in severe multiple trauma patients. No signiﬁcant clinical
effect was observed [20]. Serini et al. stated the necessity to further study the exact relationships
Fig. 4. Interplay between deﬁcient, normal, supplemented and toxic levels of n-3. Insufﬁcient intakes of n-3 FA or the presence
of a pathological condition can cause the loss of these FA and therefore a deﬁcit from the normal levels. Omega 3 intake in this case
will replace ﬁrstly the lack of FAs and restore its level to normal, further intake will increase n-3 levels above the normal where it
will act as a real supplement until the toxicity threshold is reached.
V. Silva, P. Singer / Clinical Nutrition Experimental 1 (2015) 1e98between the actual dosages of FAs ingested, the portion of them that is adsorbed, and the beneﬁcial
effects observed, as a strategy to help to deﬁnitely establish the levels of intake sufﬁcient to induce a
beneﬁcial effect without producing secondary oxidative effects, which are more likely to be observed
with high doses and long periods of supplementation (>6 months) [1]. In these sense, when designing
a supplementation plan the beneﬁcial effects should be balanced against the potential detrimental
effects of n-3 intake. Negative observations associated with very low and high dietary intake of the n-3
FA, EPA and DHA were reported [19].
Considering the contradictory data among publications and the widespread use/prescription of
n-3 supplements for health improvement in normal and pathological conditions, it is necessary to
validate the biomarkers of n-3 intake among these individuals and associate them with disease risk,
prevalence and outcome [1,19]. Whether the amount of n-3 intake is deﬁcient, adequate or
excessive should be addressed in particular, and for that it is necessary to know and understand the
initial or baseline status of the object in study, either as a whole study population, or ideally,
individually for each subject. In a patient that has deﬁcient levels of n-3 FAs, either due to insuf-
ﬁcient intake or to the presence of a disease that may induce its decrease; any n-3 intake will be
used ﬁrst to replace this decrease in FAs until “normal” cellular levels are reached. Only after this
compensation is accomplished, the supplementation may achieve pharmacological effects. If the
subject continues to be supplemented, then the risk threshold of toxicity will be reached and
negative effects are more likely to be observed (Fig. 4). The interplay between all these thresholds
and their association with health and disease should be further investigated to better design
supplementation plans.5. Conclusion
Baseline RBC-FA proﬁle proved to be different and dependent on the nature of the study population,
being the healthy group the one with better n-3 status. Moreover, we showed that for an ICU-trauma
patients group, the n-3 supplementation-associated changes are dependent on the initial n-3 FA status.
Thus, RBC-FA proﬁle should be evaluated and considered individually for each patient or groups before
generalized supplementation schemes, strengthening the concept of personalized medicine.Conﬂict of interest
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